期刊
HUMAN MOLECULAR GENETICS
卷 31, 期 8, 页码 1293-1307出版社
OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddab317
关键词
-
资金
- National Institutes of Health/National Institute of Neurological Disorders and Stroke [R01NS113765]
- National Institutes of Health/National Institute of General Medical Sciences [T34 GM136493]
- National Institutes of Health Post -baccalaureate Research Education Program [R25GM064120]
- Missouri Spinal Cord Injury/Disease Research Program [R01 HL153612]
This study describes a new mouse model of SMARD1, which mimics the characteristics of the disease such as motor neuron degeneration and muscle atrophy. The disease phenotype, including respiratory defects, can be significantly alleviated by gene therapy.
Spinal muscular atrophy with respiratory distress type I (SMARD1) is a neurodegenerative disease defined by respiratory distress, muscle atrophy and sensory and autonomic nervous system defects. SMARD1 is a result of mutations within the IGHMBP2 gene. We have generated six Ighmbp2 mouse models based on patient-derived mutations that result in SMARD1 and/or Charcot-Marie Tooth Type 2 (CMT2S). Here we describe the characterization of one of these models, Ighmbp2(D564N) (human D565N). The Ighmbp2(D564N/D564N) mouse model mimics important aspects of the SMARD1 disease phenotype, including motor neuron degeneration and muscle atrophy. Ighmbp2(D564N/D564N) is the first SMARD1 mouse model to demonstrate respiratory defects based on quantified plethysmography analyses. SMARD1 disease phenotypes, including the respiratory defects, are significantly diminished by intracerebroventricular (ICV) injection of ssAAV9-IGHMBP2 and the extent of phenotypic restoration is dose-dependent. Collectively, this model provides important biological insight into SMARD1 disease development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据